Skip to main content
Premium Trial:

Request an Annual Quote

New Products: IDT's NGS Panels; CeGaT's Skin Disease Test; Syapse Software


Integrated DNA Technologies has launched two next-gen sequencing-based disease panels.

The xGen Inherited Disease Panel was designed in collaboration with Emory Genetics Laboratory and targets all the exons of genes in the Human Gene Mutation Database. The xGen Pan-Cancer Panel is based on the findings of the Cancer Genome Atlas and targets coding regions in 127 genes implicated in 12 tumor types.

Both panels feature xGen Lockdown Probes, which are 120-mer oligonucleotides with a 5' biotin modification.

The Center for Genomics and Transcriptomics has launched 11 next-gen sequencing panels for the diagnosis of hereditary skin diseases. Sequencing is performed on Illumina's HiSeq 2500 and potentially pathogenic variants are validated with capillary sequencing. The panels range in size from 7 genes to 55 genes and can be ordered individually or in combination.

Syapse plans to make third-party commercial omics interpretation providers' content available to hospitals and laboratories through the Syapse platform to enable clinical interpretation, reporting, and decision support. It will also make public and open databases like ClinVar, COSMIC, PhenoDB, and OMIM accessible through its platform.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.